Heart Medicines — Medication Guide, Uses & Safety — Uses, Dosage & Side Effects | MyMedicPlus

Heart medicines encompass a broad and complex range of drug classes used to treat the many conditions affecting the cardiovascular system, including heart failure, coronary artery disease, stable angina, acute coronary syndromes, cardiac arrhythmias (particularly atrial fibrillation), and post-heart attack management. Cardiovascular diseases remain the leading cause of death globally, and evidence-based cardiac pharmacotherapy has been shown to dramatically improve survival, reduce hospital readmissions, and improve quality of life. Major cardiac drug categories include: ACE inhibitors and ARBs (for heart failure and post-MI remodeling prevention); beta-blockers (for heart failure, rate control, and coronary disease); loop diuretics (for fluid overload in heart failure); mineralocorticoid receptor antagonists — MRAs (spironolactone, eplerenone — for heart failure); the ARNI sacubitril/valsartan (Entresto) for heart failure with reduced ejection fraction; SGLT-2 inhibitors (now approved for heart failure regardless of diabetes status); cardiac glycosides (digoxin); nitrates (for angina); antiarrhythmics (amiodarone, flecainide); and antiplatelet agents (aspirin, clopidogrel, ticagrelor, prasugrel). Treatment is highly individualized, based on precise cardiac diagnosis, imaging, and biomarkers, and typically requires combinations of multiple medications. Always follow a cardiologist's prescription exactly.

Cardiac medications treat a wide spectrum of heart conditions. Heart failure with reduced ejection fraction (HFrEF) is treated with the 'four pillars' of guideline-directed medical therapy: ACE inhibitor or ARB (or preferably sacubitril/valsartan/Entresto), beta-blocker (bisoprolol, carvedilol, metoprolol succinate), mineralocorticoid receptor antagonist (spironolactone, eplerenone), and an SGLT-2 inhibitor (dapagliflozin/Forxiga or empagliflozin/Jardiance). Loop diuretics (furosemide, bumetanide) are added for symptom relief from fluid overload. Heart failure with preserved ejection fraction (HFpEF) is managed primarily with SGLT-2 inhibitors (now approved regardless of diabetes status) and diuretics for congestion. Atrial fibrillation (AF): rate control uses beta-blockers (bisoprolol, metoprolol) or digoxin; rhythm control uses antiarrhythmics (amiodarone, flecainide, sotalol) or electrical cardioversion; stroke prevention uses anticoagulants (DOACs or warfarin). Stable angina: beta-blockers (first-line for symptom and event prevention), long-acting nitrates (isosorbide mononitrate), and calcium channel blockers (amlodipine). Acute angina: glyceryl trinitrate (GTN) sublingual spray or tablet. Post-MI secondary prevention: aspirin 75–100 mg, P2Y12 inhibitor (clopidogrel, ticagrelor), statin (high-dose atorvastatin), ACE inhibitor, and beta-blocker. Prescribers: cardiologists, heart failure specialists, general practitioners, and advanced specialist nurses.

Each cardiac drug class acts through a distinct molecular mechanism to achieve its therapeutic effect. Beta-blockers (bisoprolol, carvedilol, metoprolol, nebivolol) competitively block beta-1 adrenergic receptors in the heart, reducing heart rate, myocardial oxygen demand, blood pressure, and the harmful effects of chronic sympathetic nervous system activation on the failing or ischemic heart muscle. ACE inhibitors (ramipril, lisinopril) block the conversion of angiotensin I to angiotensin II, reducing systemic vascular resistance (afterload) and preventing the pathological cardiac remodeling and fibrosis that drives heart failure progression — they also reduce preload through aldosterone suppression. Sacubitril/valsartan (Entresto) combines ARB (AT1 receptor blockade) with neprilysin inhibition, increasing beneficial natriuretic peptides (BNP/ANP) that promote vasodilation and natriuresis while simultaneously blocking angiotensin II — superior to ACE inhibitors alone in HFrEF. Loop diuretics (furosemide, bumetanide) inhibit the Na-K-2Cl cotransporter in the ascending Loop of Henle, causing brisk diuresis to relieve pulmonary and peripheral edema. Digoxin inhibits Na-K-ATPase in cardiac cells, raising intracellular calcium and increasing cardiac contractility (positive inotrope); it also slows AV nodal conduction through vagal enhancement, reducing ventricular rate in AF. Nitrates (GTN, isosorbide mononitrate) release nitric oxide, dilating veins (reducing preload) and coronary arteries (reducing ischemia) to relieve angina. Amiodarone blocks multiple ion channels (sodium, potassium, calcium) and has beta-blocking activity — its broad spectrum of action makes it the most effective antiarrhythmic but also the most toxic with long-term use.

Cardiac drug dosing is extremely individualized and requires specialist expertise in titration and monitoring. Representative dosing examples: bisoprolol for heart failure — start 1.25 mg once daily, titrate up every 2 weeks to target 10 mg daily; ramipril — 2.5 mg twice daily titrated to 5 mg twice daily; sacubitril/valsartan — 24/26 mg twice daily titrated up to 97/103 mg twice daily; spironolactone — 25–50 mg once daily; furosemide — 20–80 mg daily or twice daily, adjusted to achieve and maintain euvolemia; digoxin — 0.0625–0.25 mg once daily (target serum level 0.5–0.9 nmol/L in AF/heart failure — lower end preferred); GTN spray for acute angina — 0.4 mg sublingual, may repeat after 5 minutes if no relief, up to 3 sprays — call emergency services if chest pain not relieved after 3 sprays; isosorbide mononitrate (chronic angina) — 25–60 mg once daily as an asymmetric dosing regimen (with a nitrate-free interval overnight) to prevent tolerance; aspirin 75–100 mg once daily for secondary prevention; ticagrelor 90 mg twice daily post-ACS (for 12 months then reassess). All cardiac medicines require individualized titration under cardiologist supervision — dose changes must never be made without medical guidance.

Cardiac medicines carry important class-specific side effects that require regular monitoring. Beta-blockers: fatigue and exercise intolerance are extremely common at higher doses (30–40%); cold extremities and Raynaud's phenomenon; depression and sleep disturbance; erectile dysfunction in men (approximately 10%); beta-blockers can precipitate acute bronchospasm in asthmatic patients and must be used with extreme caution or avoided in asthma and significant COPD. Beta-blockers mask the tachycardia warning sign of hypoglycemia — important in insulin-dependent diabetics. In heart failure, beta-blockers are started at very low doses and titrated slowly to avoid acute decompensation during initiation. ACE inhibitors and ARBs: dry cough (ACE inhibitors — 10–20%, resolves on switching to ARB); first-dose hypotension (particularly in volume-depleted patients); hyperkalemia; and acute kidney injury (a rise in creatinine of up to 30% on starting is acceptable, but must be monitored). Loop diuretics: hypokalemia (low potassium — risk of arrhythmias with digoxin, requiring potassium supplementation or combination with potassium-sparing diuretics); hyponatremia; volume depletion and dehydration; and elevated uric acid precipitating gout. Digoxin has a dangerously narrow therapeutic window — toxicity (which can be fatal) causes nausea, vomiting, yellow-green visual halos/disturbances, bradycardia, and potentially life-threatening ventricular arrhythmias. Toxicity risk is greatly increased by hypokalemia, hypomagnesemia, and renal impairment — monitor electrolytes and kidney function closely. Amiodarone causes significant organ toxicity with long-term use: thyroid dysfunction (both hypothyroidism and hyperthyroidism — in 15–20% of long-term users), pulmonary toxicity (pneumonitis/fibrosis — in 1–5%), liver toxicity (transaminase elevation), photosensitivity and grey-blue skin discoloration, corneal microdeposits (almost universal, usually asymptomatic), and peripheral neuropathy — requires annual thyroid function, liver function, lung function, and eye examination monitoring.

Never stop heart medicines abruptly without medical guidance — this can cause acute decompensation, rebound angina, dangerous arrhythmias, or acute MI. Abrupt beta-blocker withdrawal in patients with coronary artery disease is particularly dangerous and can precipitate myocardial infarction. Digoxin toxicity is potentially fatal and must be recognized immediately: nausea, vomiting, yellow-green visual disturbances, bradycardia below 60 bpm, and any new arrhythmia in a patient on digoxin must prompt urgent medical review and serum digoxin level measurement. Hypokalemia (from loop diuretics, diarrhea, poor intake) dramatically sensitizes the heart to digoxin toxicity — potassium must be maintained within the normal range. Amiodarone has extensive and clinically serious drug interactions: it significantly raises warfarin levels (INR roughly doubles — warfarin dose must be reduced by approximately 30–50% and monitored frequently); it raises digoxin levels (reduce digoxin dose by 50%); and it raises the levels of statins (avoid simvastatin above 20 mg with amiodarone). Heart failure patients should weigh themselves daily and report any weight gain exceeding 1–2 kg over 1–3 days — this indicates fluid retention and may require diuretic dose adjustment. Report any new or worsening symptoms immediately: chest pain, increasing breathlessness at rest or minimal exertion, ankle swelling, palpitations, near-fainting, or syncope (loss of consciousness). All patients with cardiac conditions should have an up-to-date list of all medications to share with every healthcare provider, including dentists and surgeons before any procedure.